Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc is experiencing a positive financial trajectory, with a revised 2025 revenue estimate of $387.3 million, up from $374.0 million, bolstered by the company's robust second-quarter performance and growth in its surgical business segment. The company's reported revenue for the most recent quarter reached $98.6 million, marking a year-over-year increase of approximately 13%, driven by significant contributions from its wound care portfolio and surgical products. Despite a 16% year-over-year rise in selling, general, and administrative expenses to $64.2 million, the strong revenue growth in both the wound care and surgical divisions indicates a favorable outlook for the company's financial health.

Bears say

MiMedx Group Inc has experienced a decline in its gross margin, decreasing from approximately 83% to 81% in the second quarter of 2025, primarily due to production variances and product mix issues. Despite reiterating guidance for low double-digit year-over-year revenue growth and a 20% adjusted EBITDA margin, concerns loom over the volatility in reimbursement rates from CMS, which could adversely affect the company's financial performance. These factors contribute to a general negative outlook on MiMedx Group’s stock, highlighting potential challenges in maintaining profitability and revenue growth.

MiMedx Group (MDXG) has been analyzed by 2 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 2 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.